NCT02648672

BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects

A Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetic Profile of BPN14770 in Healthy Male and Female Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Tetra Discovery Partners · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a randomized double-blind (investigator and subject blinded), placebo controlled ascending single dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy male and female subjects. Each subject will be randomized to receive either a single dose of BPN14770 or placebo.

Detailed description

Objectives: 1. To evaluate the safety and tolerability profile of single oral ascending dose levels of BPN14770 in healthy subjects. 2. To characterize the BPN14770 plasma pharmacokinetic profile following oral administration.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	BPN14770	BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
DRUG	Placebo

Timeline

• Start date: 2015-12-01
• Primary completion: 2016-02-01
• Completion: 2016-07-01
• First posted: 2016-01-07
• Last updated: 2017-01-18

Locations

1 site across 1 country: United States